Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

Mounjaro, which is the brand name for tirzepatide, was shown to be even more powerful than Ozempic in a recent study with adults who were overweight or obese.

Tirzepatide in Mounjaro is more effective for weight loss than semaglutide in Ozempic, analysis finds. Drug is approved as a weight-loss treatment Zepbound.

Researchers have examined real-world data on the effectiveness on weight loss from using Ozempic and Mounjaro, and the latter drug has reportedly come out way ahead. NBC’s Christine Romans breaks down the findings on TODAY.

New diabetes drug Mounjaro is more effective for weight loss that the popular drug Ozempic, a new analysis found. The analysis conducted by Truveta Research found that patients taking Eli Lilly’s diabetes drug Mounjaro were “significantly more likely” to experience 5 percent,